Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11352407 Ultra-long acting insulin-Fc fusion proteins

Patent 11352407 was granted and assigned to Akston Biosciences Corporation on June, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
0
Current Assignee
Akston Biosciences Corporation
Akston Biosciences Corporation
0
Date Filed
December 7, 2020
0
Date of Patent
June 7, 2022
0
Patent Applicant
Akston Biosciences Corporation
Akston Biosciences Corporation
0
Patent Application Number
17114395
0
Patent Citations
‌
US Patent 10870686 Ultra-long acting insulin-FC fusion proteins and methods of use
‌
US Patent 10947292 Ultra-long acting insulin-Fc fusion proteins and methods of use
‌
US Patent 10894089 Long-acting insulin or insulin analogue conjugate
‌
US Patent 10961294 Ultra-long acting insulin-Fc fusion proteins and methods of use
0
‌
US Patent 10597435 Insulin-Fc fusions and methods of use
‌
US Patent 10709766 Fusion proteins
‌
US Patent 10822386 Insulin analogues with enhanced stability and reduced mitogenicity
‌
US Patent 10851147 Ultra-long acting insulin-Fc fusion proteins and methods of use
Patent Citations Received
‌
US Patent 11667689 Insulin-Fc fusion proteins and methods of use to treat cancer
0
Patent Inventor Names
Thomas M. Lancaster
0
Todd C. Zion
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
11352407
0
Patent Primary Examiner
‌
G. R. Ewoldt
0

Find more entities like US Patent 11352407 Ultra-long acting insulin-Fc fusion proteins

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo